Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Cerebellum. 2022 Aug 12;22(5):790–809. doi: 10.1007/s12311-022-01424-1

Table 2.

Characteristics of the longitudinal S-Factor cohort

SCA1 (N=54) SCA2 (N=56) SCA3 (N=121) SCA6 (N=50) Overall (N=281)
Baseline age 49.2 (10.6), [25.4, 68.9] 47.0 (12.3), [14.5, 67.4] 49.9 (11.0), [19.6, 73.5] 62.4 (10.3), [31.2, 80.2] 51.4 (12.2), [14.5, 80.2]
Gender (female;male) 32;22 32;24 59;62 29;21 152;129
Baseline total SARA score 9.68 (5.25), [1.00, 28.5] 14.6 (5.27), [5.50, 28.0] 11.2 (7.64), [0.500, 33.0] 12.9 (7.09), [2.00, 32.0] 11.9 (6.88), [0.500, 33.0]
Age at disease onset 41.4 (10.2), [24.0, 65.0] 36.7 (12.1), [4.00, 62.0] 40.3 (11.6), [15.0, 68.0] 52.8 (10.5), [25.0, 70.0] 42.0 (12.4), [4.00, 70.0]
Baseline disease duration 7.73 (5.12), [0.0100, 25.0] 10.3 (6.03), [0.320, 26.9] 9.56 (8.72), [0, 48.2] 9.56 (9.58), [0.500, 43.1] 9.36 (7.84), [0, 48.2]
CAG expansion repeat length Qe 46.4 (3.68), [41.0, 56.0] 39.9 (4.12), [34.0, 60.0] 71.6 (4.01), [60.0, 81.0] 22.4 (0.942), [21.0, 26.0] 51.7 (19.2), [21.0, 81.0]
Number of visits with a SARA assessment 3.17 (1.34), [2.00, 7.00] 2.98 (1.00), [2.00, 5.00] 3.24 (1.29), [2.00, 9.00] 3.34 (1.26), [2.00, 7.00] 3.19 (1.24), [2.00, 9.00]
Duration of follow-up 2.57 (2.74), [0.364, 11.1] 2.19 (2.22), [0.460, 9.27] 2.12 (2.16), [0.384, 10.7] 2.34 (2.50), [0.499, 9.95] 2.26 (2.34), [0.364, 11.1]

Mean (standard deviation), [range]